SS
GLMD icon

SBI Securities’s Galmed Pharmaceuticals GLMD Stock Holding History

SBI Securities’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37 Buy
8
+6
+300% +$30 ﹤0.01% 3733
2026
Q1 		$8 Hold
2
– – ﹤0.01% 3864
2025
Q4 		$12 Hold
2
– – ﹤0.01% 3852
2025
Q3 		$22 Sell
2
-263
-99% -$3.38K ﹤0.01% 3895
2025
Q2 		$3.89K Buy
265
+263
+13,150% +$3.09K ﹤0.01% 2108
2025
Q1 		$23 Hold
2
– – ﹤0.01% 3822
2024
Q4 		$51 Buy
+2
New +$54 ﹤0.01% 3639

Other funds holding GLMD

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SBI Securities's GLMD Position: Q2 2026 in Review

SBI Securities increased its Galmed Pharmaceuticals (GLMD) stake by 300% in Q2 2026, buying an estimated $30 and bringing the position to 8 shares worth $37. The position accounts for ﹤0.01% of the portfolio, ranked #3733.

SBI Securities first reported a position in GLMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $3.89K in Q2 2025. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

  • SBI Securities held 8 shares of Galmed Pharmaceuticals worth $37 as of Q2 2026.
  • SBI Securities bought 6 Galmed Pharmaceuticals shares in Q2 2026, an estimated $30.
  • Galmed Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3733 holding.
  • SBI Securities first reported a position in Galmed Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Galmed Pharmaceuticals position peaked at $3.89K in Q2 2025.
  • 11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.